Mind Medicine (MindMed) Inc. (FRA:MMQ)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.04B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -143.27M |
| Shares Out | n/a |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 615 |
| Average Volume | 267 |
| Open | 10.73 |
| Previous Close | 10.26 |
| Day's Range | 10.50 - 10.73 |
| 52-Week Range | 4.29 - 12.21 |
| Beta | n/a |
| RSI | 56.69 |
| Earnings Date | Mar 5, 2026 |
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. [Read more]
News
MNMD: Canaccord Genuity Raises Price Target to $25, Maintains Buy Rating | MNMD Stock News
MNMD: Canaccord Genuity Raises Price Target to $25, Maintains Buy Rating | MNMD Stock News
RBC Capital Lowers Price Target for MNMD While Maintaining Outperform Rating | MNMD Stock News
RBC Capital Lowers Price Target for MNMD While Maintaining Outperform Rating | MNMD Stock News
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
Q3 2025 Mind Medicine (MindMed) Inc Earnings Call Transcript
Q3 2025 Mind Medicine (MindMed) Inc Earnings Call Transcript
MindMed (MNMD) Strengthens Financial Position with $259M Offering
MindMed (MNMD) Strengthens Financial Position with $259M Offering
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
MindMed (MNMD) Q3 2025 Earnings Call Transcript
MindMed (MNMD) Q3 2025 Earnings Call Transcript
MindMed (MNMD) Secures Strong Financial Position for Key Developments in 2026
MindMed (MNMD) Secures Strong Financial Position for Key Developments in 2026
MindMed Reports Q3 2025 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
MindMed to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Announces New Employee Inducement Grant
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed to Report Q3 2025 Financial Results on November 6, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and extend...
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health di...
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidat...
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
MindMed to Participate in September Investor Conferences
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Mind Medicine (MNMD 1.32%) is a clinical stage biotech company that's aiming to bring psychedelics and other compounds to market as forms of treatments for conditions including generalized anxiety dis...
1 Reason to Buy MindMed (MNMD)
By their nature, clinical-stage biotech companies can be volatile investments. Even by that standard, MindMed (MNMD 2.59%) is quite a risky play; after all, a key element of its business strategy is t...
MindMed (MNMD) Q2 Net Loss Jumps 625%
Mind Medicine (MindMed) (MNMD -7.26%), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The compa...